NEW YORK (GenomeWeb) – Vermillion said today that it has entered into a share repurchase agreement with Quest Diagnostics.

Under the agreement, Vermillion on June 17, 2015 purchased from Quest 860,595 shares of its common stock for a total of around $1.3 million, or $1.50 per share.

The share price was based on a simple average of closing prices per share of Vermillion's common stock for a trailing 60-day period and was then reduced by an amount negotiated by the two parties.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.